论文部分内容阅读
根据哒嗪酮类化合物的构效关系和作用机制，以ＣＣＩ１７８１０ 为先导化合物，设计合成了１８ 个６［４（ 取代哌嗪基） 苯基］４，５二氢３（２ Ｈ）哒嗪酮类化合物．初步的体外药理试验表明：大部分目标化合物都有不同程度的抑制ＡＤＰ诱导的新西兰大白兔血小板聚集的作用，其中化合物（５）的活性最强，比先导化合物强５ 倍，化合物（６），（７） ，（１２） ，（１３） ，（１６） 的活性也比ＣＣＩ１７８１０ 强，并初步探讨了它们的构效关系．
According to the structure-activity relationship of pyridazinones and the mechanism of action, we designed and synthesized 18 6 [4 (substituted piperazinyl) phenyl] 4,5dihydro3 (2 H) pyridazinone compounds. Preliminary pharmacological experiments in vitro showed that most of the target compounds inhibited platelet aggregation in New Zealand white rabbits to some extent. Among them, compound (5) had the strongest activity and was 5-fold stronger than that of lead compounds. Compounds (6), The activities of (7), (12), (13) and (16) were also stronger than that of CCI-17810 and their structure-activity relationship was also discussed.